The myRisk™ Hereditary Cancer test assesses 25 genes for mutations associated with eight hereditary cancers. Finding deleterious mutations in these genes can help patients with cancer receive appropriate medical care and reduce the risk of second cancers, while patients without cancer can take steps in consultation with their healthcare provider to lower their risk of developing cancer.
Courtagen’s rxSEEK™ Epilepsy drug metabolism test identifies an individual’s susceptibility to adverse effects of AEDs, providing powerful information to physicians in determining an effective course of treatment.
New cancer tests that sequence only a patient’s tumor and not normal tissue could result in a significant number of false positive results, potentially leading doctors to prescribe treatments that might not work, U.S. researchers said on Wednesday. The issue is that few of these tests look at DNA from healthy cells to compare which mutations patients were born with and which are unique to the cancer, said Dr. Victor Velculescu of Johns Hopkins and a principal in Personal Genome Diagnostics, a company co-founded by the researchers.
Courtagen added the nucSEEK® Focus Nuclear Mitochondrial Gene Panel and epiSEEK® Focus Epilepsy and Seizure Disorder Panel to the company’s test offerings. The new tests will complement the current nucSEEK® Comprehensive Nuclear Mitochondrial Exome Panel and epiSEEK® Comprehensive Epilepsy and Seizure Disorder Panel, respectively. Physicians will now have more flexibility to choose the most appropriate test for their patient.
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the expanded agreement, Myriad’s BRACAnalysis CDx™ test will be used to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza™ (olaparib). Lynparza is a PARP (poly-ADP ribose polymerase) inhibitor being developed by AstraZeneca.